User profiles for Paul Leeson

Paul Leeson

- Verified email at nottingham.ac.uk - Cited by 17659

Paul Leeson

- Verified email at cardiov.ox.ac.uk - Cited by 15661

Artificial Intelligence in Cardiovascular Imaging: JACC State-of-the-Art Review

D Dey, PJ Slomka, P Leeson, D Comaniciu… - Journal of the American …, 2019 - jacc.org
Data science is likely to lead to major changes in cardiovascular imaging. Problems with
timing, efficiency, and missed diagnoses occur at all stages of the imaging chain. The …

The influence of drug-like concepts on decision-making in medicinal chemistry

PD Leeson, B Springthorpe - Nature reviews Drug discovery, 2007 - nature.com
The application of guidelines linked to the concept of drug-likeness, such as the'rule of five',
has gained wide acceptance as an approach to reduce attrition in drug discovery and …

The role of ligand efficiency metrics in drug discovery

AL Hopkins, GM Keserü, PD Leeson… - Nature reviews Drug …, 2014 - nature.com
The judicious application of ligand or binding efficiency metrics, which quantify the molecular
properties required to obtain binding affinity for a drug target, is gaining traction in the …

The UK Biobank imaging enhancement of 100,000 participants: rationale, data collection, management and future directions

…, N Doherty, AF Frangi, NC Harvey, P Leeson… - Nature …, 2020 - nature.com
UK Biobank is a population-based cohort of half a million participants aged 40–69 years
recruited between 2006 and 2010. In 2014, UK Biobank started the world’s largest multi-modal …

A comparison of physiochemical property profiles of development and marketed oral drugs

…, P Barton, AM Davis, PD Leeson - Journal of medicinal …, 2003 - ACS Publications
The process of drug discovery applies rigorous selection pressures. Marketed oral drugs
will generally possess favorable physiochemical properties with respect to absorption, …

Molecular property design: does everyone get it?

PD Leeson, RJ Young - ACS Medicinal Chemistry Letters, 2015 - ACS Publications
The principles of molecular property optimization in drug design have been understood for
decades, yet much drug discovery activity today is conducted at the periphery of historical …

An analysis of the attrition of drug candidates from four major pharmaceutical companies

…, J Arrowsmith, AR Leach, PD Leeson… - Nature reviews Drug …, 2015 - nature.com
The pharmaceutical industry remains under huge pressure to address the high attrition rates
in drug development. Attempts to reduce the number of efficacy- and safety-related failures …

Time-related differences in the physical property profiles of oral drugs

PD Leeson, AM Davis - Journal of medicinal chemistry, 2004 - ACS Publications
Comparisons of the calculated physicochemical properties of oral drugs launched prior to
1983 (864 drugs) and between 1983 and 2002 (329 drugs) show that mean values of …

Is there a difference between leads and drugs? A historical perspective

…, AM Davis, SJ Teague, PD Leeson - Journal of chemical …, 2001 - ACS Publications
To be considered for further development, lead structures should display the following
properties: (1) simple chemical features, amenable for chemistry optimization; (2) membership to …

The design of leadlike combinatorial libraries

SJ Teague, AM Davis, PD Leeson… - Angewandte Chemie …, 1999 - Wiley Online Library
The optimization of low‐potency leads into drugs is often accompanied by an increase in
molecular weight (M r ) and lipophilicity, as a consequence of affinity enhancement. Hits with …